IGF-1 LR3 — Technical Research Profile

Molecular and structural context

Long R3 IGF-1 is an 83-amino-acid IGF-1 analogue containing an N-terminal extension and an Arg substitution at position 3. These changes reduce interaction with several IGF-binding proteins relative to native IGF-1 and are used experimentally to study prolonged ligand availability.

Mechanistic research framework

IGF1R is a receptor tyrosine kinase. Ligand-induced receptor autophosphorylation recruits IRS and SHC adaptor proteins, creating experimentally measurable outputs through AKT/mTOR-associated metabolic signalling and MAPK-associated proliferation and differentiation pathways.

It is commonly used in laboratory models examining IGF-axis signalling, receptor activation, cellular growth responses, and nutrient-sensitive metabolic pathways.

Experimental applications and endpoint selection

Appropriate endpoints may include receptor phosphorylation, AKT or ERK activation, transcriptional response, cell-cycle distribution, nutrient uptake, and concentration-response kinetics. Native IGF-1 and vehicle controls help separate analogue-specific effects from general IGF1R activity.

This material is intended for analytical, biochemical, receptor-pharmacology, cellular, or other controlled preclinical workflows as appropriate to the target system. Study design should define the biological matrix, exposure duration, concentration range, replicate structure, acceptance criteria, and statistical plan before data collection.

Principal areas of scientific inquiry

• IGF-1 receptor binding and downstream signalling
• Cell proliferation and differentiation models
• Metabolic and nutrient-response pathway research

Technical keywords

• Receptor phosphorylation
• AKT/mTOR signalling
• MAPK signalling
• IGF-binding protein interactions

Analytical characterization considerations

Because IGF-family peptides may adsorb to surfaces and may be influenced by binding proteins in serum-containing systems, matrix composition, low-binding labware, incubation time, and sample recovery should be documented. Intact-mass LC-MS, peptide mapping, and size-sensitive methods can support identity and aggregation assessment.

Where scientifically appropriate, laboratories may use orthogonal methods such as reversed-phase HPLC for chromatographic purity, LC-MS for molecular identity, size-sensitive methods for aggregation, and a target-relevant functional assay for biological activity. Method suitability, reference standards, system suitability, and acceptance limits must be independently established; these examples are not batch-specific analytical claims.

Study design and interpretation

Use vehicle, positive, negative, and concentration-matched controls appropriate to the assay. Receptor expression, biological matrix, incubation time, adsorption, proteolysis, passage number, and species background can all change apparent potency or pathway output. Observations from in vitro or animal models should not be extrapolated to human use.

Handling and documentation

Use calibrated equipment and documented receipt, storage, preparation, aliquoting, freeze-thaw, and disposal procedures. Solvent compatibility, working concentration, stability window, container adsorption, and assay recovery must be established by the purchasing laboratory using the applicable batch documentation and institutional standard operating procedures.

Important compliance and safety remarks

• No therapeutic, diagnostic, cosmetic, or veterinary claims are made.
• Work must be performed by qualified personnel under applicable institutional and regulatory requirements.
• Use appropriate personal protective equipment and controlled laboratory procedures.

For research use only. Not for human or animal consumption.